Medarex struck a deal to partner with Organon on the development of new therapies based on human antibodies. The deal gives Organon access to Medarex's Ultimab human antibody technology for programs in cancer and autoimmune diseases. Researchers have been concentrating on antibodies as they seek new proteins that can be used to fight off infections. No financial details were released, but the companies agreed to share revenue from any new products they develop.
- check out the AP report